Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 8/2011

01-08-2011 | Miscellaneous

Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study

Authors: K. Froelich, A. Radeloff, C. Köhler, R. Mlynski, J. Müller, R. Hagen, N. H. Kleinsasser

Published in: European Archives of Oto-Rhino-Laryngology | Issue 8/2011

Login to get access

Abstract

In 2003, osteonecrosis of the jaw was described as an intraoral complication of bisphosphonate therapy. More recently, cases of avascular necrosis of the hip were reported in patients with long-lasting bisphosphonate therapy. Thus, it was the aim of the present study to analyze cases of benign osteonecrosis of the external ear canal and to retrospectively identify a possible relationship to long-lasting bisphosphonate therapy. 13 patients with osteonecrosis of the external ear canal operated on between 2005 and 2009 were included. Patient histories were reviewed for possible previous or current bisphosphonate therapy. Three patients with osteonecrosis of the external ear canal and long-term bisphosphonate therapy could be identified. They had been treated either for breast cancer or multiple myeloma. Certainly, the jaw is an area of increased risk for developing osteonecrosis with its high mechanical stress and intraoral bacterial flora. However, osteonecrosis of the hips and the external ear canal in patients receiving long-term bisphosphonate therapy necessitate further investigation of a possible systemic, bisphosphonate-related phenomenon.
Literature
1.
Steiner B, Lenz JH, Gundlach KK, Freund M (2005) Osteonecrosis of the jaws during treatment with bisphosphonates: diagnosis and therapy. Dtsch Med Wochenschr 130:2142–2145PubMedCrossRef
2.
Fleisch H, Russell RG, Bisaz S, Casey PA, Mühlbauer RC (1968) The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcif Tissue Res Suppl: 10–10a
3.
Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocrine Rev 19:80–100CrossRef
4.
5.
Fleisch H, Russell RG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262–1264PubMedCrossRef
6.
Francis MD, Russell RG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264–1266PubMedCrossRef
7.
Sarin J, DeRossi SS, Akintoye SO (2008) Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14:277–285PubMedCrossRef
8.
Suleman YF, Meer S, Lurie R (2007) Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report. Head Neck Pathol 1:156–164PubMedCrossRef
9.
Badros A, Weikel D, Salama A et al (1996) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952CrossRef
10.
Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA (2009) Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115:1631–1637PubMedCrossRef
11.
Abe Y, Kawakami A, Nakashima T et al (2000) Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells. J Lab Clin Med 136:344–354PubMedCrossRef
12.
Itoh F, Aoyagi S, Furihata-Komatsu H et al (2003) Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur J Pharmacol 477:9–16PubMedCrossRef
13.
Green JR, Clézardin P (2002) Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 25(6 Suppl1):S3–S9PubMedCrossRef
14.
Woo SB, Hellstein JW, Kalmar JR (2006) Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed
15.
Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117PubMedCrossRef
16.
Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575PubMedCrossRef
17.
Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857–869PubMedCrossRef
18.
Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836PubMedCrossRef
19.
Fehm T, Beck V, Banys M, Lipp HP et al (2009) Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112:605–609PubMedCrossRef
20.
Kumar BN, Walsh RM, Sinha A, Courteney-Harris RG, Carlin WV (1997) Benign necrotizing osteitis of the external auditory meatus. J Laryngol Otol 111:269–270PubMed
21.
Tsikoudas A, Davis BC (2009) Benign necrotizing otitis externa. Ear Nose Throat J 88:E18PubMed
22.
Wolf M, Nusem-Horowitz S, Zwas ST, Horowitz A, Kronenberg J (1997) Benign osteonecrosis of the external ear canal. Laryngoscope 107:478–482PubMedCrossRef
23.
Youngs R, Kwok P, Hawke M (1988) Benign osteitis of the external auditory meatus. J Otolaryngol 17:302–307PubMed
24.
Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854PubMedCrossRef
25.
Bassett CA, Donath A, Macagno F, Preisig R, Fleisch H, Francis MD (1969) Diphosphonates in the treatment of myositis ossificans. Lancet 2:845PubMedCrossRef
26.
Jowsey J, Riggs BL, Kelly PJ, Hoffman DL, Bordier P (1971) The treatment of osteoporosis with disodium ethane-1, 1-diphosphonate. J Lab Clin Med 78:574–584PubMed
27.
Russell RG, Smith R (1973) Diphosphonates. Experimental and clinical aspects. J Bone Joint Surg Br 55:66–86PubMed
28.
Smith R, Russell RG, Bishop M (1971) Diphosphonates and Paget’s disease of bone. Lancet 1:945–947PubMedCrossRef
29.
Khan AA, Sándor GK, Dore E (2009) Canadian Taskforce on osteonecrosis of the Jaw: bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 36:478–490PubMedCrossRef
30.
Sarasquete ME, González M, San Miguel JF, García-Sanz R (2009) Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 15:382–387PubMedCrossRef
31.
Diel IJ, Bergner R, Grötz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol 5:475–482PubMed
32.
Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104:83–93PubMedCrossRef
33.
Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14:35–41PubMedCrossRef
34.
Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suárez MA, Aguiar Morales J (2007) Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 18:556–560PubMedCrossRef
35.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, for the Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral, Maxillofacial Surgeons (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw—2009 update. Aust Endod J 35:119–130PubMedCrossRef
36.
Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548–1558PubMedCrossRef
37.
Ziebart T, Pabst A, Klein MO, Kämmerer P, Gauss L, Brüllmann D, Al-Nawas B, Walter C et al. (2009) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig [Epub ahead of print]
38.
Santini D, Vincenzi B, Avvisati G, Dicuonzo G et al (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080–1084PubMed
39.
Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF (2009) Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 144:667–676PubMedCrossRef
40.
Landesberg R, Cozin M, Cremers S et al (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66:839–847PubMedCrossRef
41.
Simon MJ, Niehoff P, Kimmig B, Wiltfang J, Açil Y (2010) Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Investig 14:51–58PubMedCrossRef
Metadata
Title
Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study
Authors
K. Froelich
A. Radeloff
C. Köhler
R. Mlynski
J. Müller
R. Hagen
N. H. Kleinsasser
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
European Archives of Oto-Rhino-Laryngology / Issue 8/2011
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-011-1496-z

Other articles of this Issue 8/2011

European Archives of Oto-Rhino-Laryngology 8/2011 Go to the issue

Miscellaneous

A new tool measuring oral malodor quality of life

Head and Neck

The follow-up of patients with head and neck cancer: an analysis of 1,039 patients

Head and Neck

Vitamin D status is associated with disease-free survival and overall survival time in patients with squamous cell carcinoma of the upper aerodigestive tract

Head and Neck

Expression of CD34 and CD105 as markers for angiogenesis in oral vascular malformations and pyogenic granulomas

Laryngology

Transoral CO2 laser management for selected supraglottic tumors and neck dissection

Editorial

Controversies about the central compartment in thyroid cancer